Alzheimer’s drug lecanemab hailed as momentous breakthrough

One of the world’s main researchers behind the entire thought of focusing on amyloid 30 years in the past, Prof John Hardy, stated it was “historic” and was optimistic “we’re seeing the beginning of Alzheimer’s therapies”. Prof Tara Spires-Jones, from the University of Edinburgh, stated the outcomes had been “a big deal because we’ve had a 100% failure rate for a long time”.